India is the leading pharmaceutical exporter. The Indian pharmaceutical industry has the highest number of US Food and Drug Administration (USFDA) licensed manufacturing facilities outside the US and more than 1,300 manufacturing facilities compatible with Good Industrial Practices by the World Health Organization (WHO). As the world is facing shortages of protective equipment, testing kits, and antibiotics, the entire world is desperately expecting India to fill in the critical supplies. It is necessary for the manufacturers to turn most of the lines to boost the production of medicines that are mandatory to fight novel coronavirus. India will encourage the expanded development of essential coronavirus drugs, such as hydroxychloroquine, test kits, and accompanying equipment.

India plans to ship or airlift all the vital drugs. Reviving public-sector pharmaceutical companies such as Indian Drugs and Pharmaceuticals Ltd (IDPL) and Hindustan Antibiotics Ltd (HAL) should be the major manufacturers to boost development key medicines including active pharmaceutical ingredients (APIs) and main starting materials (KSMs). The planet needs such diversified suppliers.

Indian drug producers import 60% of the APIs from other countries, for many of the APIs the dependence is 80-90%. This can leave us helpless during such pandemic. So a new policy model for pharmaceuticals is needed that will increase the production of medicines and manufacturing capacity of APIs and KSMs.